NIH Considers Exclusive License for Novel Central Nervous System Disorder Therapeutics
June 05, 2025
June 05, 2025
WASHINGTON, June 5 (TNSFR) -- The U.S. Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke and the National Center for Advancing Translational Sciences is considering granting an exclusive patent license to Psycala Bio Inc.
This notice, an action by the agency, concerns inventions related to exceptionally selective D2 Dopamine Receptor Antagonists as potential therapeutics.
These novel compounds, . . .
This notice, an action by the agency, concerns inventions related to exceptionally selective D2 Dopamine Receptor Antagonists as potential therapeutics.
These novel compounds, . . .